Magenta Therapeutics Announces Additional Preliminary Positive Results From Ongoing Phase 2 Clinical Trial Of Mgta-145 And Plerixafor In Patients With Multiple Myeloma At The American Society Of Clinical Oncology (asco) Annual Meeting
Excerpt from the Press Release:
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 4, 2021–
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced additional positive results from a Phase 2 clinical trial of MGTA-145 and plerixafor in patients with multiple myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021.
“We are very pleased to see continued favorable results for MGTA-145 and plerixafor for stem cell mobilization and collection in patients with multiple myeloma,” said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. “These results build on those previously disclosed from this study and the Phase 1 trials to further demonstrate MGTA-145 and plerixafor’s potential as a rapid, reliable, well-tolerated approach to stem cell mobilization and collection, which has positive implications for patients and donors.”
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?